Across TCGA pan-cancer cohorts, ASAH2B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ASAH2B data layer compared with 26 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ASAH2B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ASAH2B expression acts as an unfavorable survival marker.
BRCA are the cancer types where ASAH2B Mutation most reproducibly stratifies survival.